title: Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan.
abstract: BACKGROUND
  The aim of this study was to compare the effects of nebivolol and telmisartan on left ventricular mass (LVM) and midwall mechanics in mild-to-moderate hypertension.
  
  
  METHODS
  A total of 40 patients with mild-to-moderate hypertension were randomized to receive either nebivolol (2.5 to 5.0 mg/day) or telmisartan (40 to 80 mg/day) to achieve a target diastolic blood pressure of <90 mm Hg. Blood pressure (BP) was measured with sphygmomanometry, and LVM and midwall fractional shortening (mFS) were estimated by two-dimensionally guided M-mode echocardiography at baseline and at 3-month follow-up.
  
  
  RESULTS
  Age, sex distribution, and baseline SBP and DBP and heart rate were similar in the two groups. Both nebivolol and telmisartan reduced systolic (156 +/- 7 v 124 +/- 8 mm Hg, P < .01, and 153 +/- 5 v 120 +/- 7 mm Hg, P < .01, respectively) and DBP (99 +/- 4 v 80 +/- 2 mm Hg, P < .01 and 98 +/- 2 v 80 +/-2 mm Hg, P < .01, respectively) and increased mFS (16% +/- 2% v 19% +/- 2%, P < .01, and 15% +/- 2% v 18% +/- 2%, P < .01, respectively). The LVM indices decreased significantly with both nebivolol (98 +/- 16 v 84 +/- 13 g/m(2), P < .01) and telmisartan (97 +/- 13 v 83 +/- 8 g/m(2), P < .01). We found that mFS was inversely related to DBP in the nebivolol but not in the telmisartan group.
  
  
  CONCLUSIONS
  In mild-to-moderate hypertension, nebivolol and telmisartan are equally effective in reducing BP and increasing mFS. There may be differences between nebivolol and telmisartan regarding the mechanism of increase in mFS.
authors.affiliation: Department of Cardiology, Larissa University Hospital, Larissa, Greece.
authors.forename: Katerina
authors.initials: K
authors.lastname: Fountoulaki
authors.forename: Vasilis
authors.initials: V
authors.lastname: Dimopoulos
authors.forename: John
authors.initials: J
authors.lastname: Giannakoulis
authors.forename: Elias
authors.initials: E
authors.lastname: Zintzaras
authors.forename: Filippos
authors.initials: F
authors.lastname: Triposkiadis
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D003971:Diastole; D004452:Echocardiography; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000000981:diagnostic imaging / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000503:physiopathology; D009200:Myocardial Contraction / Q000187:drug effects; D000068577:Nebivolol; D012039:Regional Blood Flow; D012720:Severity of Illness Index; D000077333:Telmisartan; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol; D000077333:Telmisartan